Federal rescheduling didn’t lift all boats. It lifted one boat, the medical one, and left adult-use tied to the dock. If you’re buying, selling, or raising money on a cannabis company in 2026, that split is now the biggest single variable in cannabis rescheduling business valuation: a dollar of medical profit and a dollar of adult-use profit are no longer taxed the same way, so they are no longer worth the same.
This guide to cannabis rescheduling business valuation covers what actually changed, why it moves price, and the diligence questions that separate a real medical premium from a seller’s wishful spreadsheet.
Cannabis Rescheduling Business Valuation Starts Here: What the Order Actually Did
In April 2026 the Justice Department issued a final order, published in the Federal Register on April 28, 2026, moving two categories of marijuana from Schedule I to Schedule III: marijuana in drug products that have cleared FDA review, and marijuana subject to a state medical marijuana license. You can read the order on the Federal Register.
Everything else, including adult-use marijuana, stayed in Schedule I. DEA held a hearing on broader rescheduling from June 29 through mid-July 2026, and as of late September the administrative law judge’s recommended decision was still pending. So the split is real today, and it could narrow later, which is why any cannabis rescheduling business valuation done this year needs a plan for both outcomes. Our federal cannabis rescheduling 2026 explainer tracks the process, and Cannabis Legalization News covered the hearing as it happened.
How Does Cannabis Rescheduling Change Business Valuation?
It changes after-tax cash flow, and buyers pay for after-tax cash flow. Section 280E of the tax code only disallows deductions for businesses trafficking in Schedule I or II substances. Medical marijuana under a state license is now Schedule III, so medical activity escapes 280E while adult-use activity does not.
Read the statute yourself at 26 U.S.C. § 280E. It’s one sentence long and it has been eating cannabis margins for years. For medical operators, that sentence stopped applying. For cannabis rescheduling business valuation, that’s the whole ballgame: identical gross revenue can now produce very different net income depending on which license it runs through.
The Treasury Rules That Drive the Numbers
On April 23, 2026, Treasury and the IRS announced how tax guidance will work after the order. Two points matter for deal pricing:
- Full-year transition. Rescheduling generally will be treated as applying for a business’s full taxable year that includes the order’s effective date. A calendar-year medical operator gets relief for all of 2026, not just the months after April.
- Apportionment for mixed businesses. For businesses with multiple activities, 280E applies only to the activities tied to Schedule I or II trafficking, “e.g., by apportioning expenses.”
That second point is where cannabis rescheduling business valuation gets interesting. A dual-licensed company doesn’t get all-or-nothing treatment. It gets an allocation, and allocations are only as good as the books behind them. We walk through the tax history in 280E retrospective relief for medical marijuana.
Pricing a deal around the medical/adult-use split? Talk to our cannabis M&A counsel before the letter of intent locks in a number you can’t defend.
Why a Medical License Can Now Be Worth More in a Cannabis Rescheduling Business Valuation
Take two dispensaries with the same revenue and the same operating costs. One sells under a state medical license. The other sells adult-use. The medical store can deduct rent, payroll, and marketing like any normal business. The adult-use store, still under 280E, largely can’t. Same top line, different bottom line, different price. That is cannabis rescheduling business valuation in one sentence.
How big the gap is depends on the target’s cost structure, so we won’t pretend there’s a universal multiple. But the direction is not in doubt, and in our core states it plays out differently:
- Florida. The market is medical-only after the 2024 adult-use amendment fell short of the 60% it needed, so every Medical Marijuana Treatment Center sits on the favorable side of the line. See our Florida MMTC license transfer guide for how those deals close, and the state’s Office of Medical Marijuana Use for the program itself.
- Illinois. Starting September 10, 2026, adult-use dispensaries can apply for a Medical Cannabis Dispensing Organization “15-37 License” under 410 ILCS 705/15-37, with a $5,000 application fee, per the IDFPR adult-use cannabis program. A store that adds medical sales creates a medical revenue stream a buyer can price separately. CLN has the application details.
- Michigan. The state still licenses medical facilities separately under the MMFLA through the Cannabis Regulatory Agency, so which license a Michigan target actually sells under deserves a hard look.
For the operator-side view of what a medical license is worth, Collateral Base looks at medical license value under Schedule III.
Five Diligence Questions for Cannabis Rescheduling Business Valuation
A seller claiming a medical premium should be able to answer all five of these with documents, not adjectives.
1. What license is the revenue actually under?
The order covers marijuana “subject to a state medical marijuana license.” Pull the licenses, then pull the point-of-sale data showing which sales ran under which authority. A store that sells mostly adult-use while holding a medical license is not a medical business for pricing purposes.
2. Can the books support an expense allocation?
If the target runs both programs, Treasury’s apportionment approach means someone has to split shared costs between medical and adult-use. Ask how the target plans to do it and whether its accounting system can prove it. A clean allocation is worth money. A guess is a future audit.
3. Does the target have its DEA registration, and will it survive the deal?
Schedule III activity requires DEA registration, and the new rules give state medical licensees an expedited path. But a DEA registration can’t be assigned or transferred without DEA’s written consent under 21 CFR 1301.52(b). In an asset deal, plan for the buyer to need its own. That’s a new closing condition most cannabis purchase agreements weren’t written to handle.
4. What tax positions has the target already taken?
Has the target filed returns claiming deductions, or amended prior returns? Those positions become the buyer’s problem in a stock or membership-interest deal. Tax reps, a specific indemnity, and escrow sized to the exposure belong in the agreement.
5. What happens to the price if the law moves again?
If broader rescheduling pulls adult-use into Schedule III, today’s medical premium shrinks. If the order is narrowed or challenged, it could grow or reverse. Don’t pay a fixed premium for a variable fact. Earn-outs, price adjustments tied to regulatory events, or a lower base price with upside all let the deal flex with the law.
Structuring Around the Split
The smartest 2026 deals treat cannabis rescheduling business valuation as two valuations stapled together: one for medical cash flow, one for adult-use cash flow, each with its own tax profile and its own regulatory risk. Then the purchase agreement assigns who carries each risk.
That usually means separate revenue schedules in the reps, a DEA registration covenant, tax indemnities that survive closing, and the usual state change-of-ownership approval as a condition. The state approval side hasn’t changed; our cannabis license transfer rules by state hub covers who approves what. The diligence checklist on our cannabis due diligence attorney page is the place to start the document request.
Frequently Asked Questions
Is a medical cannabis license worth more than an adult-use license after rescheduling?
In most cannabis rescheduling business valuation work, often yes, because medical activity under a state medical license is now Schedule III and escapes Section 280E, while adult-use activity remains Schedule I. The size of the premium depends on the business’s costs and on how cleanly its revenue is separated.
Does 280E still apply to dual-licensed dispensaries?
To the adult-use side, yes. Treasury has said that for businesses with multiple activities, 280E applies only to the Schedule I or II activity, for example by apportioning expenses.
Does a buyer inherit the seller’s DEA registration?
Not automatically. Under 21 CFR 1301.52(b), a DEA registration cannot be assigned or transferred without DEA’s written consent, so buyers should plan for their own registration or for consent as a closing condition.
Could the medical valuation premium disappear?
It could shrink. DEA’s hearing on broader rescheduling finished in July 2026 and a decision is pending. If adult-use moves to Schedule III, the tax gap between the two narrows.
The Bottom Line
Rescheduling turned one cannabis market into two for tax purposes, and price follows tax. Cannabis rescheduling business valuation is now a two-column exercise. Buyers should demand proof of the medical revenue they’re paying for; sellers with clean medical books should stop accepting adult-use pricing. Either way, get cannabis M&A counsel involved before the valuation becomes a signed number.
This article is general information about cannabis business law and federal tax developments as of September 2026. It is not legal or tax advice, and reading it does not create an attorney-client relationship. Rescheduling and IRS guidance are still developing; confirm current law and consult a qualified tax advisor before acting. Howard Law Group advises cannabis clients in Illinois, Missouri, Wisconsin, Michigan, Ohio, New York and Florida.
